Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bryostatin 1 in Alzheimer's Disease
NCT02221947Phase 2Terminated
- Sponsor
- Synaptogenix, Inc.
- Start
- Jun 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Bryostatin 1 with Placebo (2 arms). Primary endpoints: Number of Participants With Adverse Events as a Measure of Safety and Tolerability at 2 weeks and Preliminary Efficacy of a Single Dose of Bryostatin in the Treatment of Patients With AD at 48 hours. Started Jun 2014; status: terminated.
02
Drugs
bryostatin-1
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02221947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02221947.